-
Mashup Score: 23Sarcomas Developed in Patients with Lynch Syndrome are Enriched in Pleomorphic Soft-Tissue Sarcomas and Are Sensitive to Immunotherapy. - 2 day(s) ago
Sarcomas do not belong to the Lynch Syndrome (LS)-tumour spectrum. A growing body literature has reported sarcomas in patients with LS. Clinical and tumour characteristics of these patients remain unknown.
Source: www.ejcancer.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 22Sarcomas Developed in Patients with Lynch Syndrome are Enriched in Pleomorphic Soft-Tissue Sarcomas and Are Sensitive to Immunotherapy. - 16 day(s) ago
Sarcomas do not belong to the Lynch Syndrome (LS)-tumour spectrum. A growing body literature has reported sarcomas in patients with LS. Clinical and tumour characteristics of these patients remain unknown.
Source: www.ejcancer.comCategories: General Medicine News, CardiologistsTweet-
A great news for Christmas: a new article by our daughter as coauthor in the #EJCancer . As usual, as cardiologist, I don’t understand the title 😎 link https://t.co/2VZPEVbo9B https://t.co/7LcycawSza
-
-
Mashup Score: 0
novel treatment options for metastatic renal cell carcinoma (mRCC), combination therapies with immune checkpoint inhibitors, phase III clinical trials evaluating immune-based combinations in mRCC, treatment-naïve mRCC.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet-
Immune-based combinations for the treatment of metastatic #RenalCellCarcinoma: a meta-analysis of randomised #ClinicalTrials. #BeyondTheAbstract with @fmassari79. #ReadNow on UroToday > https://t.co/b68EYFw9BY #EJCancer https://t.co/CxrqTnC0VD
-
-
Mashup Score: 0
novel treatment options for metastatic renal cell carcinoma (mRCC), combination therapies with immune checkpoint inhibitors, phase III clinical trials evaluating immune-based combinations in mRCC, treatment-naïve mRCC.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Immune-based combinations for the treatment of metastatic #RenalCellCarcinoma: a meta-analysis of randomised #ClinicalTrials. #BeyondTheAbstract with @fmassari79. #ReadNow on UroToday > https://t.co/b68EYFeyKq #EJCancer https://t.co/GIBLcQeS0P
-
-
Mashup Score: 4
novel treatment options for metastatic renal cell carcinoma (mRCC), combination therapies with immune checkpoint inhibitors, phase III clinical trials evaluating immune-based combinations in mRCC, treatment-naïve mRCC.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet-
Immune-based combinations for the treatment of metastatic #RenalCellCarcinoma: a meta-analysis of randomised #ClinicalTrials. #BeyondTheAbstract with @fmassari79. #ReadNow on UroToday > https://t.co/b68EYFeyKq #EJCancer https://t.co/aUHplDTiMg
-
A great news for Christmas: a new article by our daughter as coauthor in the #EJCancer . As usual, as cardiologist, I don’t understand the title 😎 link https://t.co/2VZPEVbo9B https://t.co/7LcycawSza